HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.

Published

Journal Article

The treatment of anemia with erythropoiesis-stimulating agents and iron supplementation has become the standard of care in patients with chronic kidney disease. Because of the risks associated with this approach, hypoxia inducible factor stabilizing prolyl hydroxylase inhibitors were developed as a potential treatment alternative. In recent phase 2 trials, these agents raised hemoglobin in a predictable and controlled manner and improved markers of iron metabolism. More experience is needed to establish long-term efficacy, tolerability, and safety, and to determine whether their use is associated with lower iron requirements.

Full Text

Duke Authors

Cited Authors

  • Wyatt, CM; Drüeke, TB

Published Date

  • November 2016

Published In

Volume / Issue

  • 90 / 5

Start / End Page

  • 923 - 925

PubMed ID

  • 27742192

Pubmed Central ID

  • 27742192

Electronic International Standard Serial Number (EISSN)

  • 1523-1755

International Standard Serial Number (ISSN)

  • 0085-2538

Digital Object Identifier (DOI)

  • 10.1016/j.kint.2016.08.016

Language

  • eng